PMD Device Solutions AB

Equities

PMDS

SE0021513645

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:59:44 08/05/2024 BST 5-day change 1st Jan Change
8.45 SEK -1.17% Intraday chart for PMD Device Solutions AB +7.64% -25.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology CI
PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million. CI
PMD Device Solutions to Purchase Coala-Life Group's US Unit MT
PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB. CI
PMD Device Solutions AB Begins Preparation for First German Hospital Pilot CI
PMD Device Solutions to Complete Reverse Stock Split; Shares Soar MT
Promore Pharma AB will Change its Ticker to PMDS from PROMO CI
Promore Pharma AB will Change its Name to PMD Device Solutions AB CI
Promore Pharma AB Announces Board Appointments CI
Pmd Device Solutions AB completed the acquisition of Promore Pharma AB (OM:PROMO) in a reverse merger transaction. CI
Transcript : Promore Pharma AB - Special Call
Promore Pharma to Buy PMD Device Solutions via Reverse Acquisition; Stock Skyrockets MT
Pmd Device Solutions AB intends to acquire Promore Pharma AB (OM:PROMO) in a reverse merger transaction for approximately SEK 130 million. CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Promore Pharma Enters Voluntary Liquidation MT
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Promore Pharma AB Announces CFO Change CI
Promore Pharma AB Announces CEO Change CI
Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Promore Pharma AB Auditor Raises 'Going Concern' Doubt CI
Transcript : Promore Pharma AB - Special Call
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide CI
Promore Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart PMD Device Solutions AB
More charts
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. PMDS Stock
  4. News PMD Device Solutions AB
  5. PMD Device Solutions to Purchase Coala-Life Group's US Unit